Comparing SFA-002 with Otezla for moderate plaque psoriasis
Part of Skin clinical trials.
This study compares an investigational oral medication (SFA-002) with an approved oral medication (Otezla) and a placebo for people with moderate plaque psoriasis. It aims to see if the new drug works better and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had chronic plaque psoriasis for at least 6 months.
- Psoriasis covers at least 10% of your body surface area (roughly the size of 10 palms).
- Your psoriasis is rated as moderate (score of 3 on a 5-point scale).
- You have not used apremilast (Otezla) or the study drug SFA-002 before.
- You do not have other types of psoriasis (like guttate or pustular) or other skin conditions that could interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug, HB0017, in adults with moderate to severe plaque psoriasis. If you have had psoriasis for at least 6 months and have not used certain biologic treatments, you may be able to join.
This Phase 1 study tests a new drug (SFA002) in adults with stable plaque psoriasis. It mainly focuses on safety and how the body responds, and may eventually help people with psoriasis plaques.
This trial tests an investigational drug called ORKA-002 for people with moderate-to-severe plaque psoriasis. It aims to see how well different doses work and if they are safe. You may qualify if your psoriasis covers at least 10% of your body or if it has not responded well enough to other treatments.
This study tests an investigational medicine (HS-20118) for people with moderate-to-severe plaque psoriasis. The goal is to see if the drug can safely and effectively reduce psoriasis symptoms and improve quality of life.
This study tests a new medicine (HS-20137) for moderate-to-severe plaque psoriasis, a condition causing thick, scaly patches on the skin. It aims to see if this medicine can safely reduce the severity of psoriasis and improve quality of life.
This trial tests a new oral medication, CS32582, for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at reducing skin symptoms like redness, thickness, and scaling.
Hear when a new Psoriasis (PsO) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.